Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND CVE:EMH NYSE:MRP NYSEAMERICAN:PZG NYSE:REN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$200.59-2.3%$199.43$118.03▼$216.45$12.66B0.41465,903 shs366,251 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsMRPMillrose Properties$33.09+0.8%$33.59$19.00▼$36.00$5.45BN/A1.47 million shs1.18 million shsPZGParamount Gold Nevada$1.06-1.9%$1.06$0.31▼$1.41$83.77M1.26641,488 shs763,731 shsRENRESOLUTE ENERGY/SH NEW$30.91$0.00$24.60▼$39.28$715.88M3.2305,448 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.51%-1.54%+3.81%+23.96%+57.98%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%MRPMillrose Properties+0.52%+5.69%-4.23%+4.91%+3,285,799,900.00%PZGParamount Gold Nevada-2.70%-14.96%-1.82%+61.19%+167.46%RENRESOLUTE ENERGY/SH NEW0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$200.59-2.3%$199.43$118.03▼$216.45$12.66B0.41465,903 shs366,251 shsEMHEmerald Health TherapeuticsC$0.26-3.8%C$0.26C$0.15▼C$0.53C$52.28MN/A644,760 shs384,329 shsMRPMillrose Properties$33.09+0.8%$33.59$19.00▼$36.00$5.45BN/A1.47 million shs1.18 million shsPZGParamount Gold Nevada$1.06-1.9%$1.06$0.31▼$1.41$83.77M1.26641,488 shs763,731 shsRENRESOLUTE ENERGY/SH NEW$30.91$0.00$24.60▼$39.28$715.88M3.2305,448 shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-2.51%-1.54%+3.81%+23.96%+57.98%EMHEmerald Health Therapeutics0.00%0.00%0.00%0.00%0.00%MRPMillrose Properties+0.52%+5.69%-4.23%+4.91%+3,285,799,900.00%PZGParamount Gold Nevada-2.70%-14.96%-1.82%+61.19%+167.46%RENRESOLUTE ENERGY/SH NEW0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.94Moderate Buy$249.8024.53% UpsideEMHEmerald Health Therapeutics 0.00N/AN/AN/AMRPMillrose Properties 2.75Moderate Buy$35.386.91% UpsidePZGParamount Gold Nevada 3.00Buy$1.7060.38% UpsideRENRESOLUTE ENERGY/SH NEW 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ASND, REN, EMH, PZG, and MRP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/17/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$271.0010/16/2025ASNDAscendis Pharma A/SRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$203.00 ➝ $254.0010/9/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $264.0010/8/2025MRPMillrose PropertiesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform10/8/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MRPMillrose PropertiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)10/8/2025MRPMillrose PropertiesCitizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMkt Outperform$40.0010/8/2025MRPMillrose PropertiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$40.009/27/2025ASNDAscendis Pharma A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MRPMillrose PropertiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$490.75M25.22N/AN/A($1.88) per share-106.70EMHEmerald Health TherapeuticsC$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64MRPMillrose PropertiesN/AN/AN/AN/AN/AN/APZGParamount Gold NevadaN/AN/AN/AN/A$0.47 per shareN/ARENRESOLUTE ENERGY/SH NEW$303.48M2.36$4.48 per share6.90($3.31) per share-9.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$5.16N/A835.79N/A-54.94%N/A-24.31%11/13/2025 (Estimated)EMHEmerald Health TherapeuticsN/A-C$0.70N/A∞N/AN/AN/AN/AN/AMRPMillrose Properties-$246.22MN/A0.00∞N/AN/AN/AN/A10/23/2025 (Confirmed)PZGParamount Gold Nevada-$9.05M-$0.12N/A∞N/AN/A-25.81%-16.92%11/11/2025 (Estimated)RENRESOLUTE ENERGY/SH NEW-$1.23MN/A41.61∞N/A-10.10%-22.38%2.45%N/ALatest ASND, REN, EMH, PZG, and MRP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025ASNDAscendis Pharma A/S-$0.49N/AN/AN/AN/AN/A8/7/2025Q2 2025ASNDAscendis Pharma A/S-$1.42-$0.93+$0.49-$0.93$163.17 million$216.28 million7/31/2025Q2 2025MRPMillrose PropertiesN/A$0.68N/A$0.68N/A$149.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AEMHEmerald Health TherapeuticsN/AN/AN/AN/AN/AMRPMillrose Properties$2.928.82%N/AN/AN/APZGParamount Gold NevadaN/AN/AN/AN/AN/ARENRESOLUTE ENERGY/SH NEWN/AN/AN/AN/AN/ALatest ASND, REN, EMH, PZG, and MRP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/22/2025MRPMillrose Propertiesquarterly$0.739.08%10/3/202510/3/202510/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.020.69EMHEmerald Health Therapeutics35.452.972.61MRPMillrose Properties0.170.060.06PZGParamount Gold Nevada0.474.104.10RENRESOLUTE ENERGY/SH NEWN/A0.280.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AEMHEmerald Health TherapeuticsN/AMRPMillrose PropertiesN/APZGParamount Gold Nevada4.51%RENRESOLUTE ENERGY/SH NEWN/AInsider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%EMHEmerald Health TherapeuticsN/AMRPMillrose PropertiesN/APZGParamount Gold Nevada5.46%RENRESOLUTE ENERGY/SH NEW11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.70 million37.02 millionOptionableEMHEmerald Health Therapeutics161205.03 millionN/ANot OptionableMRPMillrose PropertiesN/A166.00 millionN/AN/APZGParamount Gold Nevada877.57 million73.33 millionNot OptionableRENRESOLUTE ENERGY/SH NEWN/A23.16 millionN/AOptionableASND, REN, EMH, PZG, and MRP HeadlinesRecent News About These CompaniesGeothermal power is vying to be a major player in the world’s clean-energy futureNovember 14, 2024 | nature.comNResolute Mining shares suspended in Australia as Mali government seeks $160MNovember 14, 2024 | msn.comResolute CEO still held in Mali, diplomatic sources say, as shares suspendedNovember 14, 2024 | reuters.comResolute Shares Suspended After Mali Demands $160 MillionNovember 14, 2024 | bloomberg.comAustralia's Resolute Mining confirms CEO and two other employees detained in MaliNovember 10, 2024 | reuters.comSam Altman-Backed Energy Stock Skyrockets Amid AI-Fueled Nuclear RenaissanceOctober 31, 2024 | msn.comHicks Acquisition’s Merger with Resolute Energy Corporation Approved by Stockholders and WarrantholdersAugust 19, 2024 | br.advfn.comResolute Energy Corporation Announces Closing of Business Combination with Hicks Acquisition Company I, Inc.August 19, 2024 | br.advfn.comNew Zealand’s Unique SpiritApril 12, 2024 | nationalgeographic.comNWhat’s new on Netflix and what’s leaving in April 2024April 2, 2024 | yahoo.comWhat’s Coming to Disney+ in April 2024March 29, 2024 | variety.comVPersonal FinanceFebruary 21, 2024 | foxbusiness.comWhat's New on the 2024-2025 FAFSAFebruary 14, 2024 | usnews.comGroton captain’s role in historic Resolute desksFebruary 11, 2024 | theday.comTAmazon Prime Video’s New Releases Coming in February 2024February 3, 2024 | hollywoodreporter.comHCheap Flights from Resolute to New York John F. KennedyNovember 27, 2023 | skyscanner.netSNew OpenAI CEO Emmett Shear says AI ‘doom’ risk ‘should cause you to s–t your pants’November 25, 2023 | nypost.comNBeyoncé Unleashes New ‘Renaissance’ Film Trailer Ahead of Theatrical RunNovember 13, 2023 | yahoo.comNew RenaissanceOctober 12, 2023 | outlookindia.com"Calm And Resolute": Japan Joins India, Others In Rejecting New China MapSeptember 17, 2023 | ndtv.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Bullish Case Remains Intact Despite Recent OfferingBy Ryan Hasson | September 24, 2025GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?By Dan Schmidt | September 22, 2025Which National Chains Do People Wish Were in Their State? [2025 Survey]By MarketBeat Staff | September 30, 2025Palantir Stock Eyes New Highs, Boosted by Boeing PartnershipBy Chris Markoch | October 1, 2025How The Weak Dollar Is Fueling These Global Stock SurgesBy Gabriel Osorio-Mazilli | September 22, 2025ASND, REN, EMH, PZG, and MRP Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$200.59 -4.62 (-2.25%) Closing price 04:00 PM EasternExtended Trading$200.36 -0.24 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Emerald Health Therapeutics CVE:EMHC$0.26 -0.01 (-3.77%) As of 04/26/2021Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.Millrose Properties NYSE:MRP$33.09 +0.25 (+0.76%) Closing price 03:59 PM EasternExtended Trading$33.03 -0.06 (-0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Millrose Properties, Inc. is a real estate investment and management company that focuses on acquiring, developing, and managing high-quality commercial properties. They are headquartered in Purchase, New York.Paramount Gold Nevada NYSEAMERICAN:PZG$1.06 -0.02 (-1.85%) Closing price 04:10 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Paramount Gold Nevada Corp., together with its subsidiaries, engages in the acquisition, exploration, and development of precious metal properties in the United States. The company primarily explores for gold and silver deposits. It holds principal interest in the Sleeper gold project, which comprises 2,474 unpatented mining claims totaling approximately 44,917 acres located in Humbolt County, Nevada. The company also holds 100% interest in the Grassy Mountain gold project that consists of 455 unpatented lode claims, 3 patented lode claims, and 9 mill site claims covering an area of approximately 8,280 acres located in Malheur County, Oregon. In addition, it has an agreement to acquire 100% interests in the Frost Project, which consists of 40 mining claims located in Oregon; and the Bald Peak project located in Mineral County, Nevada. Paramount Gold Nevada Corp. was founded in 1992 and is headquartered in Winnemucca, Nevada.RESOLUTE ENERGY/SH NEW NYSE:RENResolute Energy Corporation, an independent oil and gas company, engages in the acquisition, exploitation, exploration for, and development of oil and gas properties in the United States. Its principal project area is located in the Delaware Basin portion of the Permian Basin, Reeves County. As of December 31, 2017, it had interests in approximately 27,100 gross acres located in the Permian Basin of Texas; and its estimated net proved reserves were approximately 53.4 million barrels of oil equivalent. Resolute Energy Corporation was founded in 2004 and is based in Denver, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
